EWEvie Wren

Evie Wren

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Evie Wren has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of Histological Processing on Endogenous Elemental Contents and Distributions in Breast Cancer Tissue Sections

    by Amy V. Lovejoy, Alexander P. Morrell, Diego Mesa, Alex Griffiths, Piotr R. Golda, Kay L. Dawson, Evie Wren, Katharina Kreissig, Charles Coombes, Mark Rehkämper, et al.

    Trace metal homeostasis is critical for cellular function and often disrupted in diseases such as cancer. Spatially resolved techniques enable mapping of metal distributions within complex cellular environments, surpassing the limitations of bulk analyses. Formalin-fixed, paraffin-embedded (FFPE) tissues are widely used in research, yet the impact of FFPE processing on endogenous elemental contents and distributions remains unclear, with conflicting findings across sample types. This study evaluates the suitability of FFPE human breast carcinoma tissue sections for multielemental bioimaging by direct comparison with paired fresh frozen (FF) tissues and assesses potential sources of contamination or elemental losses during processing. Three FF human breast carcinoma specimens were bisected and processed as either FF or FFPE. Serial sections underwent analyses by laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS), alongside hematoxylin and eosin (H&E)-staining, to compare elemental profiles in whole sections and morphologically distinct regions. In parallel, FFPE processing reagents encompassing tissue-marking dyes, formalin, paraffin wax, xylene, and ethanol were analyzed via solution ICP-MS to contextualize the in situ findings. The multielemental imaging results revealed that Zn, Mn, and Fe were largely preserved in FFPE sections, supporting the continued use of such tissues for in situ metal analyses. Addition of Cu was observed for all FFPE samples, most likely caused by exposure to blue tissue-marking dye. Formalin induced variable elemental leaching, most notably affecting Mg. Paraffin wax, ethanol, and xylene contained minimal trace metal levels both before and after contact with tissues.


  • Open Access

    Identification of actionable targets using DEPArray ‐based sorting of pure carcinoma and stromal populations from formalin‐fixed paraffin‐embedded tissues followed by shallow whole‐genome sequencing

    by Georgios Nteliopoulos, Evie Wren, Amelia Rushton, Marc K Wadsley, Daniel Fernandez‐Garcia, Floriana Manodoro, Otis Agbaimoni, Ritika Chauhan, Zhao Cheng, Darren P Ennis, et al.

    Formalin‐fixed paraffin‐embedded (FFPE) tissue specimens represent precious resources for clinical genomic profiling studies, especially when coupled with comprehensive medical records. Even though next‐generation sequencing (NGS) is an effective tool to detect somatic mutations and somatic copy number alterations (sCNA), the biggest challenges in unlocking clinically translatable genomic information from FFPE tissue are low DNA yields and degraded DNA, affected by variable formalin fixation. Another issue is that the proportion of carcinoma and other noncarcinoma cells is variable and can be confounded by intratumoral heterogeneity. To explore these challenges, we isolated pure carcinoma and stromal cells using the DEPArray™ NxT system, a microchip‐based digital sorter that allows isolation of pure, homogeneous subpopulations of cells from FFPE samples. We isolated pure carcinoma and stromal cell populations from 12 FFPE tissues, including tissues from nine primary and metastatic breast cancer and three primary ovarian high‐grade serous carcinomas. This was followed by downstream shallow whole‐genome sequencing (WGS) for copy number landscape profiling (10 samples) and/or a targeted panel for somatic mutation and sCNA analysis (seven samples), subject to cell availability. Seven out of 10 samples (even some with low tumour content or of old age) produced good‐quality genomic data, detecting sCNA in all carcinoma population samples but not in the stromal populations. Mutation analysis was performed successfully in 6/7 samples and somatic mutations were detected in all of them. Our workflow enabled the identification of clinically actionable targets, including PIK3CA, ERBB2, FGFR1/2, CDK6, CCNE1, KRAS amplifications and RB, BRCA1/2 losses in patients that would direct therapy. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

  • Open Access

    Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer

    by Jacqueline A. Shaw, Karen Page, Evie Wren, Elza C. de Bruin, Ekaterina Kalashnikova, Robert Hastings, Rob McEwen, Eddie Zhang, Marc Wadsley, Emmanuel Acheampong, et al.

    PURPOSE: Here, we report the sensitivity of a personalized, tumor-informed circulating tumor DNA (ctDNA) assay (Signatera) for detection of molecular relapse during long-term follow-up of patients with breast cancer. METHODS: A total of 156 patients with primary breast cancer were monitored clinically for up to 12 years after surgery and adjuvant chemotherapy. Semiannual blood samples were prospectively collected, and analyzed retrospectively to detect residual disease by ultradeep sequencing using ctDNA assays, developed from primary tumor whole-exome sequencing data. RESULTS: Personalized Signatera assays detected ctDNA ahead of clinical or radiologic relapse in 30 of the 34 patients who relapsed (patient-level sensitivity of 88.2%). Relapse was predicted with a lead interval of up to 38 months (median, 10.5 months; range, 0-38 months), and ctDNA positivity was associated with shorter relapse-free survival ( P < .0001) and overall survival ( P < .0001). All relapsing triple-negative patients (n = 7/23) had a ctDNA-positive test within a median of 8 months (range, 0-19 months), while the 16 nonrelapsed patients with triple-negative breast cancer remained ctDNA-negative during a median follow-up of 58 months (range, 8-99 months). The four patients who had negative tests before relapse all had hormone receptor–positive (HR+) disease and conversely, five of the 122 nonrelapsed patients (all HR+) had an occasional positive test. CONCLUSION: Serial postoperative ctDNA assessment has strong prognostic value, provides a potential window for earlier therapeutic intervention, and may enable more effective monitoring than current clinical tests such as cancer antigen 15-3. Our study provides evidence that those with serially negative ctDNA tests have superior clinical outcomes, providing reassurance to patients with breast cancer. For select cases with HR+ disease, decisions about treatment management might require serial monitoring despite the ctDNA-positive result.